Resmed (RMD) Income from Non-Controlling Interests (2021)
Resmed's (RMD) quarterly Income from Non-Controlling Interests came in at $48.1 million in Q3 2021, up 183.22% quarter-over-quarter from -$57.8 million in Q2 2021.
Powered by 
Analysis
Resmed (RMD) Income from Non-Controlling Interests (2021) Analysis & Trends
Resmed (RMD) has reported Income from Non-Controlling Interests for 1 consecutive years, with $48.1 million the latest figure, recorded in Q3 2021.
- For the quarter ending Q3 2021, Income from Non-Controlling Interests changed N/A year-over-year to $48.1 million; the trailing twelve-month figure through Dec 2021 stood at $43.6 million (changed N/A YoY), and the FY2021 full-year result was -$4.5 million, up 78.27% from the prior year.
- Income from Non-Controlling Interests advanced to $48.1 million in Q3 2021 per RMD's latest filing, from -$57.8 million in the prior quarter.
- Across five years, Income from Non-Controlling Interests topped out at $53.3 million in Q1 2021 and bottomed at -$57.8 million in Q2 2021.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 177.43 Bn | 172.48 Bn | 7.27 Bn | - |
| 2 | Intuitive Surgical | 139.20 Bn | 134.11 Bn | 1.96 Bn | 6.60 Mn |
| 3 | Medtronic | 118.01 Bn | 109.81 Bn | 6.34 Bn | 9.00 Mn |
| 4 | Stryker | 105.44 Bn | 101.96 Bn | 4.50 Bn | - |
| 5 | Boston Scientific | 62.90 Bn | 62.60 Bn | 3.85 Bn | -2.00 Mn |
| 6 | Edwards Lifesciences | 50.87 Bn | 46.72 Bn | 1.35 Bn | -500,000.00 |
| 7 | Dexcom | 33.72 Bn | 31.77 Bn | 830.00 Mn | - |
| 8 | Resmed | 32.45 Bn | 30.98 Bn | 861.22 Mn | - |
| 9 | Alcon | 31.70 Bn | 30.25 Bn | 1.68 Bn | - |
| 10 | Steris | 20.01 Bn | 19.54 Bn | 684.20 Mn | 900,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2021 | 48.10 Mn |
| Jun 30, 2021 | -57.80 Mn |
| Mar 31, 2021 | 53.30 Mn |